Leonardo Roever: Exploring the Role of Glutamine Metabolism in Atherosclerosis
Leonardo Roever, CEO of Brazilian Evidence-Based Health Network, shared a post on LinkedIn about a recent article by Jiangqin Wang et al., published in Current Atherosclerosis Reports, adding:
“Glutamine Metabolism: A Metabolic Axis Connecting Vascular Remodeling and Plaque Stability in Atherosclerosis
Atherosclerosis (AS) – the pathological basis of atherosclerotic cardiovascular disease (ASCVD) – is a chronic, progressive inflammatory disease. Its major clinical events are primarily caused by plaque rupture and subsequent thrombosis.
Growing evidence suggests that metabolic reprogramming is a key regulator of vascular cell phenotypic transitions and plaque progression.
Among the various metabolic pathways, glutamine (Gln) metabolism is of particular interest because it links nutrient availability to vascular cell function – facilitating the supply of carbon and nitrogen, the maintenance of redox homeostasis, and the generation of metabolites involved in epigenetic regulation.
This review summarizes recent advances in Gln metabolism and discusses its regulatory roles in vascular remodeling and plaque stability, focusing on implications for AS pathogenesis and therapeutic strategies.”
Title: Glutamine Metabolism: a Metabolic Hub Linking Vascular Remodeling and Plaque Stability in Atherosclerosis
Authors: Jiangqin Wang, Jingwen Wang, Peng Gao, Jie Tian
Stay updated with Hemostasis Today.
-
Sep 17, 2026, 02:36Wolfgang Miesbach: Effectiveness of Avatrombopag in ITP Treatment
-
Sep 17, 2026, 02:34Aleksandar Sič: The Endothelium and Cardiovascular Toxicity in Blood Cancers
-
Sep 16, 2026, 15:45Matthew Hazell: A Brilliant Explanation of Phenotype vs Genotype Using a LEGO House
-
Sep 16, 2026, 15:23Ahmad Al-Ramahi: Presenting the Military Pharmacists Blood Training Course at the FIP World Congress
-
Sep 16, 2026, 15:21HIT Reimagined: Can 12-Lipoxygenase Inhibition Stop Immune Thrombosis?
-
Sep 16, 2026, 14:42Ruchi Punamia: Beyond the Blood Bank and The Clinical Impact of Apheresis
-
Sep 16, 2026, 14:06Kalyan Roy: Celebrating Apheresis, Advancing Care, Saving Lives
-
Sep 16, 2026, 13:38Andrew Zapfel: Advancing Sickle Cell Disease Care and Research
-
Sep 16, 2026, 13:30Thirunavukkarasu Angappan: Why Plasma-Derived Factor VIII Still Matters for Inhibitor Patients